MA31667B1 - Induction dun phenotype tolerogene dans des cellules dendritiques matures - Google Patents

Induction dun phenotype tolerogene dans des cellules dendritiques matures

Info

Publication number
MA31667B1
MA31667B1 MA32461A MA32461A MA31667B1 MA 31667 B1 MA31667 B1 MA 31667B1 MA 32461 A MA32461 A MA 32461A MA 32461 A MA32461 A MA 32461A MA 31667 B1 MA31667 B1 MA 31667B1
Authority
MA
Morocco
Prior art keywords
dendritic cells
tolerogeneous
phenotype
induction
mature dendritic
Prior art date
Application number
MA32461A
Other languages
Arabic (ar)
English (en)
Inventor
Herrera José M Carballido
Vries Jan E De
Ulf Korthaeuer
Maria Grazia Roncarolo
Silvia Adriana Gregori
Original Assignee
Novartis
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis, San Raffaele Centro Fond filed Critical Novartis
Publication of MA31667B1 publication Critical patent/MA31667B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation d'un molécule liant cd45 pour moduler la fonction de cellules dendritiques. La présente invention concerne notamment l'utilisation d'un molécule liant cd45 pour induire des cellules dendritiques tolérogènes, utiles dans le traitement de maladies telles que les maladies auto-immunes et le rejet de greffe.
MA32461A 2007-06-05 2009-12-30 Induction dun phenotype tolerogene dans des cellules dendritiques matures MA31667B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109672 2007-06-05
PCT/EP2008/056851 WO2008148761A1 (fr) 2007-06-05 2008-06-03 Induction d'un phénotype tolérogène dans des cellules dendritiques matures

Publications (1)

Publication Number Publication Date
MA31667B1 true MA31667B1 (fr) 2010-09-01

Family

ID=39721982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32461A MA31667B1 (fr) 2007-06-05 2009-12-30 Induction dun phenotype tolerogene dans des cellules dendritiques matures

Country Status (17)

Country Link
US (1) US20100183602A1 (fr)
EP (1) EP2160410A1 (fr)
JP (1) JP2010529078A (fr)
KR (1) KR20100035643A (fr)
CN (1) CN101687928A (fr)
AU (1) AU2008258646A1 (fr)
BR (1) BRPI0812205A2 (fr)
CA (1) CA2689570A1 (fr)
CL (1) CL2008001620A1 (fr)
EA (1) EA200901621A1 (fr)
IL (1) IL202230A0 (fr)
MA (1) MA31667B1 (fr)
MX (1) MX2009013220A (fr)
TN (1) TN2009000494A1 (fr)
TW (1) TW200907061A (fr)
WO (1) WO2008148761A1 (fr)
ZA (1) ZA200908089B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347774B1 (fr) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Echafaudages pour transplantation cellulaire
WO2009002401A2 (fr) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Échafaudages pour recueil ou élimination de cellules
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2011014871A1 (fr) * 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programmation de cellules à des fins de thérapie tolérogénique
EP2305277A1 (fr) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Utilisation de cellules dendritiques tolérogéniques dans le traitement et la prévention de l'athérosclérose
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149259A1 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Nanovecteurs synthétiques tolérogènes destinés à réduire des réponses impliquant des anticorps
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
WO2013036296A1 (fr) * 2011-09-06 2013-03-14 Selecta Biosciences, Inc. Compositions et procédés de production de cellules dendritiques tolérogéniques induites, spécifiques d'un antigène, avec des nanovecteurs synthétiques
EP2838515B1 (fr) 2012-04-16 2019-11-20 President and Fellows of Harvard College Compositions de silice mésoporeuse pour moduler les réponses immunitaires
EA201592103A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Способы и композиции для усиления cd4+ регуляторных t-клеток
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
EP3250250A4 (fr) 2015-01-30 2019-05-22 President and Fellows of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN101687928A (zh) 2010-03-31
CL2008001620A1 (es) 2009-02-20
BRPI0812205A2 (pt) 2014-11-25
ZA200908089B (en) 2010-07-28
JP2010529078A (ja) 2010-08-26
TW200907061A (en) 2009-02-16
IL202230A0 (en) 2010-06-16
WO2008148761A1 (fr) 2008-12-11
MX2009013220A (es) 2010-04-09
TN2009000494A1 (en) 2011-03-31
US20100183602A1 (en) 2010-07-22
AU2008258646A1 (en) 2008-12-11
EP2160410A1 (fr) 2010-03-10
EA200901621A1 (ru) 2010-06-30
KR20100035643A (ko) 2010-04-05
CA2689570A1 (fr) 2008-12-11

Similar Documents

Publication Publication Date Title
MA31667B1 (fr) Induction dun phenotype tolerogene dans des cellules dendritiques matures
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MA34209B1 (fr) Protéines à domaine de squelette basé sur la fibronectine qui se lient à pcsk9
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
EA200800763A1 (ru) Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
MA31918B1 (fr) Agents et épitopes de liaison à wise
MX336633B (es) Variantes de fc silenciosas de los anticuerpos anti-cd40.
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MX2009008174A (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion.
SG165418A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
MA33492B1 (fr) Inhibiteurs de bace
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA33350B1 (fr) Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide
TW200618817A (en) Diffractive colorants for cosmetics
CO6341640A2 (es) \\\"tratamiento de enfermedad autoinmunitaria e inflamatoria\\\"
FR2938437B1 (fr) Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
FR2943249B1 (fr) Utilisation de la decorine pour augmenter la masse musculaire
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation